Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Status:
Recruiting
Trial end date:
2026-05-03
Target enrollment:
Participant gender:
Summary
At present, the incidence rate of breast cancer has exceeded that of lung cancer, becoming
the largest cancer in the world. HER2 overexpression breast cancer accounts for about 20%~30%
of all breast cancer patients. HER2 is an important prognostic indicator and therapeutic
target for breast cancer. Targeted therapy for HER2 protein is the core treatment of this
type of breast cancer. Previous studies have confirmed that TKI drugs can reverse the
resistance of large molecule monoclonal antibodies to a certain extent; Moreover, due to the
complementarity of therapeutic targets, monoclonal antibodies are associated with TKI Drugs
have synergistic effects. TCbHP is one of the preferred neoadjuvant chemotherapy schemes
recommended by NCCN guidelines for HER2 positive breast cancer, but its incidence of adverse
reactions such as vomiting, diarrhea, anemia, thrombocytopenia is significantly higher than
that of the scheme without platinum. In the GeparOcto study and Geparsixto study, based on
anthracycline+purple shirt+double target, the addition of carboplatin did not further improve
the PCR rate of HER2 positive breast cancer neoadjuvant therapy. GeparSepto research showed
that compared to the solvent based paclitaxel group, albumin paclitaxel increased the pCR
rate by 8.2% and the IDFS by 7.3%. In the CA024 study, compared to docetaxel, albumin
paclitaxel also significantly increased ORR and PFS. In the study by Lavasani SM et al., the
neoadjuvant therapy of albumin paclitaxel combined with topiramate achieved a PCR rate of
64%. Therefore, we assume that the new adjuvant treatment scheme of Nab PH+pyrrolitinib can
not be inferior to the efficacy of TCbHP, and has a lower incidence of adverse reactions,
which may become a new adjuvant treatment option for HER2 positive breast cancer patients.